ADVERSE DRUG REACTION REPORTING

SITE: CATEGORY: Archive Process (01) PREPARED BY: Trevor Soll APPROVED BY: SIGNED (BLUE INK): DATE SIGNED:

ADVERSE DRUG REACTION REPORTING PROCESS

INTRODUCTION

This SOP describes how to prepare and complete an Adverse Drug Reaction (ADR) in CHARMS (Canadian Haemophilia Assessment and Resource Management System).

CHARMS is an MS Access Database that is utilized by 26 Haemophilia clinics across Canada. It collects data on product distribution, clinical outcomes, adverse events, genotyping, and has clinical, nursing and study consent modules.

Confirmed ADRs are posted in CHARMS with corresponding data placed in the Health Canada ADR Report. This information is sent out to all intended recipients via the CHARMS webserver.

Responsibilities:

Haemophilia Clinics

- Tracking of patient haemophilia records in CHARMS
 - Includes product names, lot numbers, quantity, infusion diary, etc.
- Quick response to patient concerns
- Review/update of ADR reporting in patient charts and CHARMS
- Haemophilia physician approves symptoms as ADR

AHCDC

- Notifying clinic of any discrepancies and omissions of ADR submissions
- Notifying the Principle Investigator of all discrepancies and their resolution
- Review of ADR reports

** this documentation reflects the assumption that the user has basic knowledge of the CHARMS program

AMENDMENTS FROM PREVIOUS DOCUMENT

None

DOCUMENTATION REQUIRED

This SOP

Title: File name:

Version Date:	15 March, 2012	Document control #:	CHARMS-ADR-1
Print Date:	2012-03-15	Document Type:	SOP
Page:	1 of 6	Controlled copy #:	1. Master

This document is a confidential communication of the Canadian Hemophilia Assessment and Resource Management. Receipt of this document constitutes an agreement by the recipient that no unpublished information contained herein shall be published or disclosed without written approval, except that this document may be disclosed to the appropriate REB under the condition that they keep it confidential.

SITE: CATEGORY: PREPARED BY: Trevor Soll

APPROVED BY: SIGNED (BLUE INK): **DATE SIGNED:**

MATERIALS

Adverse Drug Reaction details EQUIPMENT/INSTRUMENTS

PC running the CHARMS program

PRECAUTIONS

- 01) Ensure correct patient data is entered in CHARMS.
- 02) Ensure patient name/PHN matches the Canadian Haemophilia Registry (CHR) Number that is referenced in CHARMS
- 03) It is mandatory that only one designated person at each clinic have the authority to submit this report. It will be up to the Clinic Director to make this choice.

PROCESS

A. Log into CHARMS

01) Upon logging into CHARMs, use the Infusion Diary and locate the infusion episode



02) Select the line item of product infused prior to the reaction reported by the patient.

Version Date:	22 February 2012	Document control #:	ADR01
Print Date:	2012-03-15	Document Type:	SOP
Page:	2 of 6	Controlled copy #:	1. Master

AHCDC

SITE: CATEGORY: PREPARED BY: Trevor Soll

APPROVED BY: SIGNED (BLUE INK): DATE SIGNED:



03) Click on the Reaction button and proceed to fill in the Adverse Event report.

Advorse	Deng	Constion	v3.1.0 Copyrigh	nt © 1999-2003 AHCDC
Auvers	= Diug I	reaction	Select Patie	nt Name: AlTestperson Andrew
A. Patient Info I.Patient ID: HM	mation 100995 Chart N	umber:	2. Age: 44	DOB: 01-Jan-1960 3. Sex: M 4. Height 157 5. Weight 73
B. Adverse Re	action		and the fature to	cm kg
Death Date of D	eath LifeTh	reat Hospitilized Prolo	nged Stay Disab	ility Congenital Intervention Other If Other Please Specify
Date of Reaction:	18-Apr-2004 D	ate of Report: 18-Ap	r-2004 Reactio	n Type: Reaction Length: hrs
C. Suspected [Drug Product(s)			
Prir	nary	Secon	dary]
Frequency: Route: Therapy From: 01	1-Apr-2004	To: 01-Apr-2004	dication of use of React stopp	Jan-2005 Product Pactor VIII-A Istrand Less-ATT estmanufacturer Suspected Drug Product Bleed Trauma
3.4 Heaction	B.5 Tests	B.6 History	C.9 Drugs	C.10 Treatment
		Enter you	ir descriptive inform	ation in the box below
(
D. Reporter				Addresst
D. Reporter	Hospital			Address1:
D. Reporter	✓ ✓	Ex		Addresst Address2 City Date Sent Add Ent
D. Reporter ealth Professiona ieported to Manul ntered: 18-Apr-20	Hospital Phone Phone Determined By	Ex		Addresst Address2 City Date Sent Add Exit

- A. Some cells may be pre-populated with existing data (ie UI#, last recorded weight, age, date of birth). Please review to ensure all is correct.
- B. 'Primary' product tab. This tab records the product infused as selected from the Infusion Diary to initiate the report. If there is a need to report a secondary product infused, enter the details by selecting the 'Secondary' tab.

04) Complete 'Section C' sub-tabs (B4. Reaction, B5. Tests, B6. History, C9. Drugs, C10. Treatment).

Note: Most information is to be entered manually with the exception of B5. Tests where you can select the applicable test results as well as add text. All information inputted in each section will be added on the Health Canada 'Adverse Reaction Form'

Version Date:	22 February 2012	Document control #:	ADR01
Print Date:	2012-03-15	Document Type:	SOP
Page:	3 of 6	Controlled copy #:	1. Master

SITE: CATEGORY: PREPARED BY: Trevor Soll

APPROVED BY: SIGNED (BLUE INK): DATE SIGNED:

EB Product Reaction
Adverse Drug Reaction Copyright © 1999-2000 AHCDC Select Patient Name: AtTestperson Andrew
1.Palent ID. HM 10995 Chart Number: 2. Age: 44 008: 01-Jan-1560 3. Sex M 4. Height: 157 5. Weight: 73
B. Adverse Reaction Outcome stributed to adverse reaction(deek all that appl) Dead Date of Dead (Dead) Lief Hereal Hospitized Prolonged Stay. Disabley: Corgenital Intervention Date of Reaction [18 App-2004] Out of Report [18 App-2004] Reaction Type Reaction Length: Net
L. Suspected Drug Product(s)
Lot # AILOTI Dore[100 Expiry[0].Jan-2005 Product[Factor VIII.A1BrandTestA1Testmanufacture] Frequency Indication of use of Suspected Drug Product [BleedTrauma Route Route Therapy From [0].Apr-2004 To[0].Apr-2004 Reaction abared after reintroduction; [1/A
B.4 Reaction B.5 Tests B.6 History C.9 Drugs C. 10 Treatment Enter your descriptive information in the box below
Corrector Corrector

B.4. Reaction



Enter patient reaction details here.

B.5. Tests

diy	Secondary
Lot #: A1LOT1	D se 100 Expiy: 01Jan-2005 Product Factor VII-A1BrandTest-A1Testmanufactur
Frequency:	Indication of use of Suspected Drug Product BleedTrauma
Route:	Beaction abated after use Reaction reappeared
erapy From: 01-Apr-2004	To: 01-Apr-2004 stopped or dose reduced Y 💌 after reintroduction: N/A 💌
D I D F Tosta	
Beaching B.D Lests	8 5 History - Survices 1. Ultreatment
	bis mouth a bridge a to troducing
act Tests: Blood 💽 Che	
act Tests: Blood 💽 Che	n Cong East Hymo Tom Viol To Nef I INFE (1) PT (1) PT (1) PT (1) PT (1) VVMult (Nama
act Tests: Blood Che agulation-Date: [01 Jan-2000] Lal /FRC0F: [1] FIX: [1] FX: [1]	No (1) NR (1) Ph (100) Interference (10 Anno 2000) Interfe
act Tests: Blood Che agulation-Diate: [01Jan-2000] Lal /FRC0F:[1] FIX:[1] FX:[1] FX:[1]	No.(1) NR.(1) PY 5050000000000000000000000000000000000
ect Tests: Blood Che agulation:Date: [01 Jan-2000] Lal VFRCOF:[1] FM:[1] FM:[1] FM:[1]	Image: Code
ect Texts: Blood • Che agulation-Date: [01.Jan-2000] Lal /FRCOF: [1] FD: [1] FX: [1] FX: [1] Reporter	Image: Control
ect Texts: Blood C Che agulation-Date: [01.Jan-2000] Lal /FRCOF:[1] FD:[1] FX:[1] FX:[1] Reporter	Addresst: Addresst: Addresst: Addresst:
ect Texts: Blood Che agulation-Date: [01-Jan-2000] Lal /FRC0F:(1) Fb:(1) Fb:(1) Fb:(1) Reporter th Professional ? From:	Image: Solution

Edit and submit on the lab results that are applicable.

B.6-10

Version Date:	22 February 2012	Document control #:	ADR01
Print Date:	2012-03-15	Document Type:	SOP
Page:	4 of 6	Controlled copy #:	1. Master

AHCDC

SITE: CATEGORY: PREPARED BY: Trevor Soll

APPROVED BY: SIGNED (BLUE INK): DATE SIGNED:

B.4 Reaction	B.5 Tests	B.6 History	C.9 Drugs	C.10 Treatment
		Enter yo	our descriptive inform	nation in the box below
Fiee text descript	ion may be entere	d here that will appear	on the Health Ca	nada "Adverse Reaction Form"
200				
A Beaction	B 5 Tests	B 6 History	C.9 Drugs	C 10 Treatment
	5.0 1000	0.0110003		
		Enter yo	our descriptive inform	hation in the box below
Fiee text descript	ion may be entere	d here that will appear	on the Health Ca	nada "Adverse Reaction Form"
3.4 Reaction	B.5 Tests	B.6 History	C.9 Druas	C.10 Treatment
		1.000		
		Enter yo	our descriptive inform	nation in the box below
Free text descript	ion may be entere	d here that will appear	on the Health Ca	nada "Adverse Reaction Form"
í .				
5				
D. Reporter 🚃		10	10	
A	1FAA1FA 🗾 D	r. A1Familydoc	A1Familydoc	Address1:
ealth Professional	?	1 Test Hospital		Address2:
longited to Manuf	Phone: (S	.05)111-1111 E	ist.: 1111	
reported to Manur.	Entered By: S	ally HeadNurse	-	Date Sent: Edit Add
	04		112	
ntered: 18-Apr-20			9	? [à ⊁∰ ∽ ▶∗

- History, Drugs and Treatment tabs will allow all the administrator to describe each section in detail.
- 05) Report Preview

It is recommended that the report be reviewed by the Clinic Director or reporting Health Professional before it is submitted. To preview the report, click on the magnifying glass. Make any revisions to the form as required.

B.4 Reaction	B.5 Tests	B.6 History	C.9 Drugs	C.10 Treatment
		Enter you	r descriptive inform	nation in the box below
Fiee text descripti	on may be entere	d here that will appear o	on the Health Car	nada "Adverse Reaction Form"
100				
B 4 Beaction	R 5 Taete	B 6 History	C.9 Drugs	C 10 Treatment
b.4 medecion	0.0 10808	D.0 matory	<u> </u>	
The short description	an and he autom	Enter you	ir descriptive inform	nation in the box below
Fiee text description	on may be entere	o nere (nat will appear d	on the Health Car	hada Adverse heaction rom
n i nasavias 1	DETerte		C 0 Davas	1 10 Treatment
b.4 neaction	D.D ests	D.6 HISCORY	C.5 Drugs	
		Enter you	ur descriptive inform	nation in the box below
Free text descript	ion may be entere	d here that will appear o	on the Health Ca	nada "Adverse Finaction Form"
D. Reporter		r A1Eamiludoc	A1E amiludoc	Addre 1
	Hospital:	1 Test Hospital	Ilern annyade	Ad
lealth Professional	? 🗹 Phone: [105) 111-1111 Ex	t.: 1111	
Reported to Manuf.	? 🗹 Entered By: S	ally HeadNurse		Date Sent: Edit Add Exit
-			104	
Intered: 18-Apr-20				ອີໄ CAL ນອງໄ ນວ່ໄ ນະໄ 🚺 🌢

06) Submitting the Adverse Event Click on the Save button to submit the ADR. Click 'Yes' on the popup box to finalize the submission.

Version Date:	22 February 2012	Document control #:	ADR01
Print Date:	2012-03-15	Document Type:	SOP
Page:	5 of 6	Controlled copy #:	1. Master

AHCDC

SITE: CATEGORY:

PREPARED BY: Trevor Soll

APPROVED BY: SIGNED (BLUE INK): DATE SIGNED:

Adverse	Drug Reaction
Auverses	Crug Iscaction Select Potient Name: All extperion Andrew
1.Patient ID: HM100	1995 Chart Number: 1234 2. Age: 44 DOB: 01-Jan-1960 3. Sex: M 4. Height 157 5. Weight 2
B. Adverse Reacti	On Outcome attributed to adverse reaction (check all that apala)
Death Date of Death	LifeThreat Hospitilized Prolonged Stay Disability Congenital Intervention Other If Other Please Specify
	Submit It Now?
Date of Reaction: 18	-Apr-2004 Dat action Length:
C. Suspected Drug	Product(s) You can't change the information once it has been submitted
Primary	
Lot # A1LC	BrendTestA1Testmanufacturer
Frequency:	Kes No peoux Y
Route	Reaction shaled after use Reaction represented
Therapy From: 02-Fe	b-2004 T a 02-Feb-2004 stopped or dose reduced: N/A 💌 after reintroduction: N/A 💌
	DET. to L DOWNER L CODAN CIU Instruct
.4 neaction	B.5 Tests B.6 History C.5 Didge C.6 Troducine
Free test may be est	Energour descriptive information in the box below
FIGS toxt may be one	and here which will be circled drive the median canada. Advance Every Tellin,
D. Reporter A1FA	VATEA - Dr. ATFamilydoc Atfamilydoc Addresay
lealth Professional ?	Hisepital AT Toot Hospital Address
Reported to Manuf.?	Entered Bis Suson Head/birse Date Sent Edit
Intered: 18-Apr-2004	
odified: 18-Apr-2004	
	Send Adverse Reaction Rpt via the Internet

END OF SOP

Version Date:	22 February 2012	Document control #:	ADR01
Print Date:	2012-03-15	Document Type:	SOP
Page:	6 of 6	Controlled copy #:	1. Master

CHARMS Adverse Reaction Reporting Process Data Flow Diagram



CHARMS ADVERSE EVENT REPORTING MODULE

EMAIL FLOWCHART ADR REPORT SENT ADR REVIEW TIME (24hrs) VERIFY ADR HAS **BEEN ACCESSED** EMAIL BOUNCEBACK/ ERROR? CONTACT P.I. OR YES GOV'T/PHARMA ACCESSED? DONE TO REQUEST UPDATED CONTACT FOLLOWUP WITH 'NON-REVIEWER' TO NO **DETERMINE IF THEY RECEIVED THE EMAIL** YES **REQUEST TO HAVE** EMAIL RECEIVED? FILE REVIEWED NO CONTACT ADR **IT SUPPORT**